ZLAB
Zai Lab Limited
NASDAQ · Healthcare · Biotechnology · CN
$26.23
−2.85%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 449.6M | 460.2M | 399.0M | 266.7M | 215.0M |
| Cost of Revenue | 195.7M | 191.1M | 147.9M | 95.8M | 74.0M |
| Gross Profit | 253.9M | 269.1M | 251.1M | 170.9M | 141.0M |
| Operating Expenses | |||||
| R&D Expense | 236.9M | 220.9M | 234.5M | 265.9M | 286.4M |
| SG&A Expense | 281.1M | 277.6M | 298.7M | 281.6M | 259.0M |
| General & Admin Expense | 252.3M | 277.6M | 298.7M | 281.6M | 197.5M |
| Selling & Marketing Expense | 28.8M | — | — | — | 61.5M |
| Other Expenses | (106.0K) | (5.9M) | — | (10.0M) | — |
| Total Operating Expenses | 517.9M | 492.6M | 533.2M | 537.5M | 545.4M |
| Cost and Expenses | 713.6M | 683.7M | 681.1M | 633.3M | 619.4M |
| Operating Income (EBIT) | (264.0M) | (223.6M) | (282.1M) | (366.6M) | (404.4M) |
| Non-Operating | |||||
| Interest Income | 27.9M | 33.0M | 37.1M | 39.8M | 14.6M |
| Interest Expense | 6.0M | 5.2M | 2.3M | — | — |
| Net Interest Income | 21.9M | 27.8M | 34.9M | 39.8M | 14.6M |
| Other Non-Op Income/Expense | 73.3M | 45.1M | 25.0M | 32.0M | (38.9M) |
| Non-Operating Income (excl Interest) | (79.3M) | (50.3M) | (27.3M) | 7.6M | 38.7M |
| EBT (Pre-Tax Income) | (190.7M) | (178.5M) | (257.1M) | (334.6M) | (443.3M) |
| Income Tax Expense | (2.5M) | (2.9M) | — | — | — |
| Bottom Line | |||||
| Net Income | (188.2M) | (175.5M) | (257.1M) | (334.6M) | (443.3M) |
| Earnings from Cont. Ops | (188.2M) | (175.5M) | (257.1M) | (334.6M) | (443.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (188.2M) | (175.5M) | (257.1M) | (334.6M) | (443.3M) |
| Per Share | |||||
| Basic EPS | ($1.79) | ($1.60) | ($2.60) | ($34.60) | ($46.30) |
| Diluted EPS | ($1.79) | ($1.60) | ($2.60) | ($34.60) | ($46.30) |
| Revenue Per Share | $4.03 | $4.20 | $4.03 | $27.60 | $22.45 |
| Shares | |||||
| Basic Shares Outstanding | 111.7M | 109.5M | 98.9M | 9.7M | 9.6M |
| Diluted Shares Outstanding | 111.7M | 109.5M | 98.9M | 9.7M | 9.6M |
| Profitability Metrics | |||||
| EBITDA | (168.8M) | (158.2M) | (234.6M) | (365.1M) | (434.8M) |
| D&A | 15.9M | 15.0M | 20.3M | 9.0M | 8.2M |
| EBIT | (184.7M) | (173.3M) | (254.8M) | (374.1M) | (443.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026